Zenith Stock
Executive Summary
Firm paid a stock dividend of 50% on issued shares of common stock March 12. The three-for-two stock split moved Zenith's March 13 opening price to 20 from 30-1/2 the previous day. The stock closed the month at 21-7/8, up 1-7/8 after the split and up 2 for the month. "The Pink Sheet" (April 8, p. 12) incurrectly reported the Zenith was the only point loser among generic firms during the month of March.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.